Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Harvard Business School
Johnson and Johnson
McKesson
Medtronic

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 7,838,239

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,838,239
Title:Methods regarding enhanced T-cell receptor-mediated tumor necrosis factor superfamily mRNA expression in peripheral blood leukocytes in patients with crohn\'s disease
Abstract: A method is disclosed for determining whether a human having Crohn\'s disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn\'s disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn\'s disease is disclosed. A method of monitoring the disease state over time in Crohn\'s disease patients is also disclosed.
Inventor(s): Mitsuhashi; Masato (Irvine, CA), Targan; Stephan R. (Santa Monica, CA)
Assignee: Hitachi Chemical Co., Ltd. (Tokyo, JP) Hitachi Chemical Research Center, Inc. (Irvine, CA) Cedars-Sinai Medical Center (Los Angeles, CA)
Application Number:12/296,425
Patent Claims:see list of patent claims

Details for Patent 7,838,239

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up Hitachi Chemical Co., Ltd. (Tokyo, JP) Hitachi Chemical Research Center, Inc. (Irvine, CA) Cedars-Sinai Medical Center (Los Angeles, CA) 2026-04-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chubb
Fish and Richardson
Covington
Harvard Business School
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.